Vascular ischaemia and reperfusion injury

Holger K. Eltzschig* and Charles D. Collard†

*Department of Anesthesiology and Intensive Care Medicine, University Hospital, Tübingen, Germany and †Department of Cardiovascular Anesthesia, Texas Heart Institute, Saint Luke’s Episcopal Hospital, Houston, TX 77030, USA

Although restoration of blood flow to an ischaemic organ is essential to prevent irreversible tissue injury, reperfusion per se may result in a local and systemic inflammatory response that may augment tissue injury in excess of that produced by ischaemia alone. Cellular damage after reperfusion of previously viable ischaemic tissues is defined as ischaemia–reperfusion (I–R) injury. I–R injury is characterized by oxidant production, complement activation, leucocyte–endothelial cell adhesion, platelet–leucocyte aggregation, increased microvascular permeability and decreased endothelium-dependent relaxation. In its severest form, I–R injury can lead to multiorgan dysfunction or death. Although our understanding of the pathophysiology of I–R injury has advanced significantly in the last decade, such experimentally derived concepts have yet to be fully integrated into clinical practice. Treatment of I–R injury is also confounded by the fact that inhibition of I–R-associated inflammation might disrupt protective physiological responses or result in immunosuppression. Thus, while timely reperfusion of the ischaemic area at risk remains the cornerstone of clinical practice, therapeutic strategies such as ischaemic preconditioning, controlled reperfusion, and anti-oxidant, complement or neutrophil therapy may significantly prevent or limit I–R-induced injury in humans.

Introduction

The consequences of depriving an organ of its blood supply have long been recognized as a critical factor in the clinical outcome of stroke, haemorrhagic shock, myocardial infarction and organ transplantation. Although restoration of blood flow to an ischaemic organ is essential to prevent irreversible tissue injury, reperfusion per se may augment tissue injury in excess of that produced by ischaemia alone. For example, the histological changes of injury after 3 h of liver or intestinal ischaemia followed by 1 h of reperfusion are far worse than the changes observed after 4 h of ischaemia alone.¹ ² Cellular damage after reperfusion of previously viable ischaemic tissues is defined as ischaemia–reperfusion (I–R) injury.³
I–R injury may occur in a variety of clinical settings, including reperfusion after thrombolytic therapy, coronary angioplasty, organ transplantation, aortic cross-clamping or cardiopulmonary bypass. Reperfusion of ischaemic tissues results in both a local and a systemic inflammatory response that, in turn, may result in widespread microvascular dysfunction and altered tissue barrier function. If severe enough, the inflammatory response after I–R may even result in the systemic inflammatory response syndrome (SIRS) or the multiple organ dysfunction syndrome (MODS), which account for up to 30–40% of intensive care unit mortality.4 Thus I–R injury may extend beyond the ischaemic area at risk to include injury of remote non-ischaemic organs. The pathophysiology, clinical manifestations and therapeutic strategies for the prevention or treatment of vascular I–R injury are reviewed.

**Pathophysiology of ischaemia–reperfusion injury**

**Cellular effects of ischaemia**

Oxygen homeostasis is fundamental to human physiology. The essential requirement for adenosine 5′-triphosphate (ATP) generation via oxidative phosphorylation is balanced by the risk of oxidative damage to cellular lipids, nucleic acids, and proteins. Thus cellular and systemic oxygen concentrations are tightly regulated via short- and long-acting response pathways affecting cellular protein expression and activity.5

Prolonged ischaemia results in multiple cellular metabolic and ultrastructural changes (Table 1). Although the hypoxic tolerance amongst cell types differs depending on the metabolic rate and intrinsic adaptive mechanisms, cellular necrosis inevitably follows extended periods of anoxia (i.e. oxygen absent) or severe hypoxia (i.e. oxygen supply decreased relative to metabolic demand). Ischaemia-induced decreases in cellular oxidative phosphorylation

<table>
<thead>
<tr>
<th>Cellular acidosis</th>
<th>Altered membrane potential</th>
<th>Altered ion distribution (increased intracellular Ca²⁺/Na⁺ ratio)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cellular swelling</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cytoskeletal disorganization</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increased hypoxanthine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decreased ATP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decreased phosphocreatine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decreased glutathione</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stabilization and nuclear translocation of hypoxia-inducible factor 1 (HIF-1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increased leucocyte adhesion molecule expression</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increased nucleotide phosphohydrolysis (via CD39 and CD73) and adenosine signalling</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Ischaemia–reperfusion injury

Regulation of vascular endothelial growth factor (VEGF) expression illustrates how reduced oxygen availability (hypoxia) can elicit physiological responses via a variety of molecular mechanisms. VEGF plays an essential role in angiogenesis. Hypoxia induces VEGF expression, thus providing a mechanism by which tissue perfusion can be optimized to demand. VEGF mRNA levels increase in hypoxic cells as a result of both increased production (transcriptional activation) and decreased destruction (mRNA stabilization). Whereas overall cell protein synthesis is inhibited in response to hypoxia, VEGF mRNA is efficiently translated into protein. The essential first step in this process, transcriptional activation, is mediated by the binding of hypoxia-inducible factor 1 (HIF-1) to a hypoxia-response element localized upstream from the 5′ transcriptional start site of the human VEGF gene. HIF-1 is a basic helix–loop–helix Per-ARNT-Sim (PAS) protein consisting of HIF-1α and HIF-1β subunits. HIF-1α protein expression is negatively regulated in non-hypoxic cells by ubiquitination and proteasomal degradation. Under hypoxic conditions, HIF-1α protein levels increase dramatically and the fraction that is ubiquitinated decreases. Thus hypoxia results in rapid nuclear accumulation of HIF-1α, where it dimerizes with HIF-1β and binds to the core DNA sequence 5′-RCGTG-3′, leading to the transcriptional activation of VEGF and many other known target genes.

Vascular effects of hypoxia

The pathogenesis of I–R injury begins with a hypoxic insult to the vascular endothelium which not only serves as a vascular barrier, but also orchestrates polymorphonuclear leucocyte (PMN) trafficking. As noted previously, hypoxia activates both transcriptional and non-transcriptional pathways, and several parallels exist between tissue responses to hypoxia and to acute inflammation. For example, PMNs are mobilized from...
the intravascular space to the interstitium during hypoxia, and such responses may contribute significantly to tissue damage during subsequent reperfusion. Moreover, myeloid cell migration to sites of inflammation is highly dependent on hypoxia-adaptive pathways. PMN migration through the endothelial barrier may disrupt such tissue barriers and create the potential for extravascular fluid leakage and oedema formation.  

Many endogenous protective mechanisms exist to fortify the vascular barrier during ischaemic insults. Activated PMNs release a variety of soluble mediators which regulate vascular permeability, including glutamate and adenine nucleotides [in the form of ATP or adenosine monophosphate (AMP) which, through metabolic conversion, liberate adenosine at the vascular surface]. In particular, adenosine protects the microvascular endothelial barrier function by helping to re-establish endothelial cell–cell contact following PMN transmigration.  

Recent studies demonstrate that hypoxia differentially influences vascular permeability in response to activated PMNs. Hypoxic endothelia demonstrate increased protective responses to activated PMNs that are mediated in part through PMN-derived ATP. Further, extracellular ATP metabolism and signalling are enhanced by hypoxia-induced transcriptional increases in functional endothelial surface apyrase (CD39), 5′-ecto-nucleotidase (CD73) and adenosine A2B-receptors (AdoRA2B). Thus, hypoxia initiates a coordinated endothelial-barrier-protective response associated with enhanced extracellular adenosine concentrations and signalling (Fig. 1).  

In contrast, PMNs also liberate factors that may disrupt the endothelial barrier. Activation of PMNs through β2 integrins stimulates the release of soluble factor(s) which induce endothelial cytoskeletal rearrangement and gap formation, and increase permeability. One PMN-derived permeabilizing factor is heparin-binding protein (HBP), also known as azurocidin or CAP37, which is a member of the serprocidin family of cationic peptides. HBP, unlike other neutrophil granule proteins (e.g. elastase, cathepsin G), induces Ca2+-dependent cytoskeletal changes in cultured endothelia and triggers macromolecular leakage in vivo. Interestingly, endothelial cells themselves were recently shown to release HBP, suggesting self-regulation of permeability under some conditions.  

Role of leucocytes  
I–R injury is characterized by leucocyte activation, chemotaxis, leucocyte–endothelial cell adhesion, and transmigration. Leucocytes interact with the vascular endothelium via a series of distinct steps characterized by leucocyte ‘rolling’ on the endothelium, firm adherence of leucocytes to the endothelium and endothelial transmigration (Fig. 2). According
Ischaemia–reperfusion injury

Fig. 1 Proposed model of coordinated nucleotide metabolism and nucleoside signalling in hypoxic endothelial cells. In areas of ongoing inflammation, diminished oxygen supply coordinates the induction of endothelial surface apyrase (CD39), 5′-ecto-nucleotidase (CD73) and adenosine A2B receptors (AdoRA2B). At such sites, activated PMNs provide a readily available extracellular source of ATP that, through two enzymatic steps, results in the liberation of extracellular adenosine. Adenosine generated in this fashion is available for surface endothelial adenosine receptor activation, particularly AdoRA2B. Post-receptor increases in intracellular cyclic AMP result in enhanced barrier function. Thus this protective mechanism may provide an innate mechanism for preserving vascular integrity and preventing fulminant intravascular fluid loss. Reproduced with permission from Eltzschig et al. (2003) J Exp Med, 198, 783–96.

to this multistep paradigm, the first step is initiated by I–R-induced increases in endothelial P-selectin (CD62P) surface expression, which interacts with its leucocyte counter-receptor P-selectin glycoprotein 1 (PSGL-1). This initial low-affinity interaction results in intermittent leucocyte–endothelial binding or ‘leucocyte rolling’. Firm leucocyte adherence results from the subsequent interaction of the leucocyte β2 integrins CD11a/CD18 and CD11b/CD18 with endothelial intercellular adhesion molecule 1 (ICAM-1). Leucocyte transmigration into the interstitial compartment is facilitated by platelet–endothelial cell adhesion molecule 1 (PECAM-1). Upon reaching the extravascular compartment, activated leucocytes release toxic ROS, proteases and elastases, resulting in increased microvascular permeability, oedema, thrombosis and parenchymal cell death. PMN accumulation in the extravascular compartment is also facilitated by interleukin 8 (IL-8) released from hypoxic tissues, resulting in a chemotactic gradient that directs neutrophils from the intravascular space towards the hypoxic interstitium.
The no-reflow phenomenon

The no-reflow phenomenon refers to the clinical observation that blood flow to an ischaemic organ is often not fully restored following the release of a vascular occlusion. Possible mechanisms include increased platelet-leucocyte aggregation, leucocyte-endothelial cell adhesion, interstitial fluid accumulation and decreased endothelium-dependent vasorelaxation.\(^7,27\) The no-reflow phenomenon may manifest clinically as continued organ dysfunction in the post-reperfusion period (e.g. myocardial stunning), failure of a transplanted graft or increased infarct size. Experimental canine studies demonstrate a central role of leucocyte adhesion/trapping in the no-reflow phenomenon, as leucocyte depletion in these models improves coronary blood flow, decreases myocardial infarction size and attenuates ventricular arrhythmias.\(^28\)

Role of reactive oxygen species

Reperfusion of ischaemic tissues results in formation of toxic ROS, including superoxide anions (O\(^2^-\)), hydroxyl radicals (OH\(^-\)), hypochlorous...
Ischaemia–reperfusion injury

acid (HOCl), hydrogen peroxide (H₂O₂) and peroxynitrite derived from NO.⁶ Cellular ischaemia results in ATP degradation to form hypoxanthine. Under normal physiological conditions, hypoxanthine is oxidized by xanthine dehydrogenase to xanthine. However, xanthine dehydrogenase is converted to xanthine oxidase during ischaemia. Unlike xanthine dehydrogenase, which uses nicotinamide adenine dinucleotide (NAD) as its substrate, xanthine oxidase uses oxygen; therefore during ischaemia it is unable to catalyse the conversion of hypoxanthine to xanthine, resulting in a build-up of excess tissue levels of hypoxanthine. When oxygen is re-introduced during reperfusion, conversion of the excess hypoxanthine by xanthine oxidase results in the formation of toxic ROS.²⁹,³⁰

ROS may cause tissue injury via several mechanisms. As they are potent oxidizing and reducing agents, ROS directly damage cellular membranes through lipid peroxidation.²⁹,³¹ ROS also stimulate leucocyte activation and chemotaxis by inducing plasma membrane phospholipase A₂ mediated formation of arachidonic acid, an important precursor of eicosanoid synthesis (e.g. thromboxane A₂ and leukotriene B₄).³¹ Finally, ROS increase leucocyte adhesion molecule and cytokine gene expression by activating transcription factors such as nuclear factor κB (NF-κB) and activator protein 1 (AP-1).³¹

Role of complement

I–R results in complement activation and the formation of several key inflammatory mediators that may alter vascular homeostasis, including the anaphylatoxins C₃a and C₅a, and the complement components iC₃b and C₅b-₉.³² C₅a is the most potent of these inflammatory mediators, being approximately 20 times more potent than C₃a. In addition to directly stimulating leucocyte activation and chemotaxis, C₅a may further amplify the inflammatory response to I–R by inducing the production and release of several pro-inflammatory cytokines, including IL-1, IL-6, monocyte chemoattractant protein 1 (MCP-1) and tumour necrosis factor α (TNF-α).³²

Vascular endothelial function may also be altered by C₅b-₉ and iC₃b. iC₃b is formed after C₃b cleavage and is a specific ligand for leucocyte adhesion to the vascular endothelium via the β₂ integrin CD11b/CD18 (Mac-1). C₅b-₉ activates endothelial NF-κB to increase leucocyte adhesion molecule transcription and expression.³² Leucocyte adhesion molecules known to be regulated by complement include vascular cell adhesion molecule 1 (VCAM-1), ICAM-1, E-selectin and P-selectin.³² C₅b-₉ has also been shown to increase leucocyte activation and chemotaxis by inducing endothelial IL-8 and MCP-1 secretion.³² Finally, C₅b-₉ may directly alter vascular tone by inhibiting endothelium-dependent relaxation and
decreasing endothelial cyclic guanosine monophosphate (cGMP). Thus complement may further compromise blood flow to ischaemic tissues by altering vascular homeostasis and promoting leucocyte–endothelial adherence.

**Clinical manifestations of ischaemia–reperfusion injury**

A wide spectrum of clinical manifestations of I–R injury has been described, ranging from transient reperfusion arrhythmias to the development of fatal MODS. While the response to I–R may vary amongst individuals, risk factors such as diabetes, hypertension or hypercholesterolaemia increase the vulnerability of the microvasculature to I–R injury.

**Myocardial stunning**

Myocardial stunning can be defined as myocardial dysfunction persisting after reperfusion despite the absence of irreversible damage. The contractile dysfunction is transient and fully reversible with time, although temporary inotropic or mechanical support may be required. Myocardial stunning should be differentiated from ‘hibernating’ myocardium, which is defined as persistent ischaemia-associated myocardial dysfunction at rest (i.e. reperfusion has not yet occurred). Mechanisms of myocardial stunning may include decreased ATP resynthesis, coronary microvasculature spasm or plugging, ROS-mediated cytotoxic injury and altered intracellular calcium release and uptake.

**Reperfusion arrhythmias**

Reperfusion arrhythmias are frequent in patients undergoing thrombolytic therapy or myocardial surgical revascularization, and may be a cause of sudden death after relief of coronary ischaemia. Further, ventricular tachycardia, ventricular fibrillation or accelerated idioventricular rhythms are often observed following myocardial I–R in animals with normal coronary arteries, particularly if reperfusion occurs abruptly after 15–20 min of ischaemia. Reperfusion arrhythmias may be in part due to rapid and sudden ion concentration changes within ischaemic tissues upon reperfusion. Staged gradual reflow or transient acid reperfusion may reduce the incidence of malignant arrhythmias. In contrast, studies of thrombolytic therapy in acute myocardial infarction patients clearly demonstrate a lower incidence of malignant arrhythmias in treated compared with non-treated patients, suggesting that reperfusion lowers the overall risk of sudden death.
Central nervous system ischaemia–reperfusion injury

Reperfusion injury of the central nervous system (CNS) may contribute to the morbidity and mortality of stroke, head trauma, carotid endarterectomy, aortic aneurysm repair and deep hypothermic circulatory arrest. I–R injury of the CNS is characterized by disruption of the blood–brain barrier, resulting in cerebral oedema, increased intracranial pressure and leucocyte transmigration into the surrounding brain tissues. Leucocytes may then release various proteases, lipid-derived mediators and ROS that may result in irreversible tissue damage, particularly within the ischaemic penumbra. Moreover, because of a loss of cerebral vasoreactivity, a reactive hyperaemia may occur which may worsen the cerebral oedema. Thus I–R injury of the CNS may manifest clinically as worsened sensory, motor or cognitive functioning and death.

Gastrointestinal ischaemia–reperfusion injury

Similar to I–R injury to the CNS, gastrointestinal (GI) I–R injury is characterized by decreased intestinal barrier function. Pathological conditions or surgical procedures where GI I–R injury may occur include strangulated bowel, haemorrhagic shock and vascular surgery producing intestinal ischaemia. Under normal physiological conditions, the intestinal barrier protects the body from the hostile environment within the bowel lumen. However, GI I–R disrupts this protective function, resulting in increased intestinal permeability and bacterial translocation into the portal and systemic circulations. GI I–R injury may also be associated with impaired gut motility and absorption. Activation of complement and circulating leucocytes by translocated bacteria may eventually lead to the development of SIRS following GI I–R.

Several innate pathways have been identified that protect intestinal barrier function during hypoxia. Under physiological conditions activation of epithelial adenosine receptors regulates chloride secretion and promotes intestinal barrier function. As mentioned previously, generation of extracellular adenosine is in part dependent on CD73-mediated conversion of AMP to adenosine. Recently, CD73 was shown to play a critical role in the maintenance of intestinal barrier function during hypoxia. Such studies may help to identify potential novel therapeutic targets that may prevent or attenuate development of SIRS following GI I–R.

Multiorgan dysfunction syndrome

A devastating consequence of I–R is the development of remote organ injury and MODS. MODS is a leading cause of death in critically ill
patients in intensive care units (ICUs), with mortality directly correlating with the number of failed organ systems.\textsuperscript{4} Risk factors for MODS include sepsis, major trauma, circulatory shock, aortic cross-clamping, burns, pancreatitis and immunological disorders.\textsuperscript{3} The pulmonary system is the most frequently injured organ in patients suffering from MODS, and the onset of the syndrome is commonly preceded by the development of acute respiratory insufficiency within 24–72 h of the initiating ischaemic event. Respiratory failure and development of acute respiratory distress syndrome (ARDS) may quickly ensue.\textsuperscript{37} Respiratory failure is often followed by hepatic, renal, gastrointestinal, myocardial and CNS dysfunction. In addition to increased microvascular permeability, MODS is characterized by dysfunction of the coagulation and immune systems, leading to thrombosis, disseminated intravascular coagulation and immunocompromise.

**Therapeutic implications**

The biotechnology and pharmaceutical industries have directed considerable effort into developing novel therapeutic strategies to limit or prevent I–R injury. Although many therapeutic strategies have been shown to be effective in controlled experimental models, most have yielded equivocal results in clinical practice or have yet to reach human clinical trials. Therefore timely reperfusion of the ischaemic area at risk remains the cornerstone of clinical practice.

**Leucocyte therapy**

Therapeutic strategies to prevent leucocyte-mediated I–R injury include inhibition of leucocyte adhesion molecule synthesis, inflammatory mediator release, receptor engagement and endothelial cell adhesion. Inflammatory mediators such as platelet activation factor (PAF), histamine, leukotriene $\text{B}_4$ ($\text{LTB}_4$), and TNF-$\alpha$ facilitate leucocyte activation. One experimental approach has been to inhibit the release or receptor engagement of such mediators using anti-TNF-$\alpha$ antibodies, soluble IL-1 receptor antagonists or PAF–$\text{LTB}_4$ antagonists.\textsuperscript{38} Additionally, aspirin has been shown to induce biosynthesis of a group of bioactive eicosanoids known as the 15-epi-lipoxins or ‘aspirin-triggered’ lipoxins.\textsuperscript{39} Lipoxins are potent inhibitors of leucocyte chemotaxis, adhesion and transmigration induced by leukotrienes and other inflammatory mediators, which suggests that they are part of innate protective pathways dampening the host inflammatory response. Administration of novel biostable lipoxin analogues has been shown to attenuate PMN-mediated
changes in vascular barrier function and second-organ injury in several experimental models of I–R.39 Thus lipoxin analogue therapy may represent a novel therapeutic strategy for preventing PMN-mediated I–R injury.

A second therapeutic approach to limiting or preventing I–R injury is to decrease leucocyte adhesion molecule synthesis. Many commonly prescribed anti-inflammatory drugs, such as aspirin, glucocorticoids, gold salts and D-penicillamine, attenuate activation of transcription factors (e.g. NF-κB, AP-1) which regulate leucocyte adhesion molecule synthesis or cytokine expression.38 Antisense oligodeoxynucleotides and transcription factor decoys have also been used successfully to attenuate leucocyte adhesion molecule expression and cytokine release.38 Antisense oligodeoxynucleotides are single-stranded DNA molecules capable of specifically binding to a complementary nucleic acid sequence, thereby blocking expression of a gene product on a translational and/or transcriptional level. In contrast, transcription factor decoys are double-stranded antisense oligodeoxynucleotides containing specific binding elements that compete for gene regulatory protein binding (e.g. NF-κB, AP-1) with the authentic nuclear binding elements, thereby interfering with gene regulation. Recently, small interfering RNA (siRNA) molecules have been successfully used in mammalian cell culture to target translation of specific gene products. Following siRNA ‘knockdown’, functional assays can be performed to determine the physiological contribution of specific gene products and their regulation.40 This experimental approach is similar to that of the gene knockout animal (e.g. knockout mice)41 and, while limited to cell culture, can be performed much more easily.

I–R injury may also be attenuated by inhibiting leucocyte–endothelial interaction. Monoclonal antibodies directed against leucocyte adhesion molecules or their soluble forms (e.g. PSGL-1, sialyl-Lewisx or ICAM-1) have been successfully used in several experimental models to prevent binding of the membrane-bound form of the adhesion molecule to its ligand.38 Although these strategies have proved extremely effective in animal models of I–R, human clinical data are limited.38

**Ischaemic preconditioning**

Repeated exposure of tissues to brief periods of ischaemia or hypoxia may protect against the harmful effects of prolonged I–R. This phenomenon is referred to as ischaemic preconditioning. In experimental models of I–R, ischaemic preconditioning has been shown to improve ventricular function and decrease myocardial neutrophil accumulation and apoptosis.42 Nonetheless, human clinical data are limited. Ischaemic preconditioning was recently shown to reduce the risk of postoperative
arrhythmias in patients undergoing coronary artery bypass graft (CABG) surgery\textsuperscript{43} and to reduce liver injury in humans undergoing hepatic resection.\textsuperscript{44}

Different mechanisms are thought to be responsible for the protective effects of acute and delayed ischaemic preconditioning in humans. Acute ischaemic preconditioning is associated with adenosine or $\alpha_1$-adrenergic receptor mediated activation of pertussis-sensitive G proteins, which in turn stimulate phospholipase C or D to activate protein kinase C (PKC). Thus, the beneficial effects of acute ischaemic preconditioning may be due in part to PKC-dependent phosphorylation of ATP-sensitive potassium channels\textsuperscript{45} and PKC-dependent translocation of 5'-nucleotidase to the endothelial cell surface, leading to increased adenosine production, augmentation of cellular energy stores and decreased leucocyte adherence.\textsuperscript{45} Although the beneficial effects of acute ischaemic preconditioning are decreased as the interval between the brief and prolonged ischaemic insults is extended beyond 2 h, a delayed protective effect of preconditioning may be observed when the prolonged ischaemic insult occurs 24 h after the initial brief periods of ischaemia.\textsuperscript{3} Unlike the acute response, delayed preconditioning is dependent on altered gene expression and synthesis of new proteins, including antioxidant enzymes, NO synthase and heat shock proteins.\textsuperscript{3}

As noted previously, adenosine is a critical factor in tissue protection during ischaemia and/or hypoxia. Ischaemic preconditioning is associated with increased extracellular adenosine formation.\textsuperscript{46} While the source of interstitial adenosine in hypoxic tissues has been the basis of much debate, it is generally accepted that CD73-mediated AMP dephosphorylation represents the major pathway of extracellular adenosine formation (Fig. 1). Indeed, CD73 is transcriptionally upregulated by hypoxia \textit{in vitro} and \textit{in vivo},\textsuperscript{22} and myocardial ischaemia has been shown to increase extracellular adenosine production.\textsuperscript{47} Similarly, myocardial ischaemic preconditioning is associated with increased CD73 activity and adenosine metabolism, suggesting a protective role for CD73 and adenosine following I–R.\textsuperscript{47}

In addition to the critical role of adenosine signalling, a role for inducible NO synthase has also been suggested in ischaemic preconditioning. For example, cyclooxygenase-2 (COX-2) is known to mediate the cardioprotective effects of delayed ischaemic preconditioning. It was recently shown that NO-mediated activation of COX-2 is the underlying signalling pathway by which NO synthase is involved in ischaemic preconditioning of the heart.\textsuperscript{48} In addition, inducible NO synthase has been shown to influence ischaemic preconditioning of both kidney\textsuperscript{49} and brain.\textsuperscript{50} This is supported by data indicating that knockout mice deficient in endothelial or neuronal NO synthases show no protection following rapid ischaemic preconditioning in a model of
transient middle cerebral artery occlusion followed by permanent occlusion of the vessel.\textsuperscript{50}

**Antioxidant therapy**

Experimental data obtained from studies using N-acetylcysteine, angiotensin-converting enzyme inhibitors, mannitol, iron-chelating compounds, catalase, superoxide dismutase, allopurinol, calcium-channel antagonists and vitamin E suggest that antioxidant therapy may prevent or attenuate I–R injury.\textsuperscript{7} A prospective trial of human recombinant superoxide dismutase in patients with haemorrhagic shock demonstrated that patients receiving 5 days of continuous intravenous superoxide dismutase had significantly less severe organ failure, fewer days in the ICU and lower serum phospholipase and PMN elastase concentrations.\textsuperscript{51} Superoxide dismutase has also been shown to promote graft survival and decrease the incidence of acute rejection after renal transplantation.\textsuperscript{52} However, many human trials of antioxidant therapy to prevent or attenuate I–R injury have yielded equivocal results. Thus, while experimental data strongly support the role of oxidative stress in I–R injury and indicate a role for antioxidant therapy, further randomized human trials are warranted.\textsuperscript{53}

**Complement therapy**

Inhibition of complement activation has been shown to reduce I–R injury significantly in many experimental models.\textsuperscript{32} Administration of soluble complement receptor 1, a C3 convertase inhibitor, significantly decreased myocardial infarction size (by 44%) in an experimental rat model.\textsuperscript{54} Similarly, a recombinant single-chain antibody specific for human C5 (pexelizumab) was shown to attenuate complement activation, leucocyte activation, myocardial injury and acute postoperative mortality significantly in humans undergoing CABG surgery.\textsuperscript{55,56} Although both these compounds, as well as several other novel anticomplement agents, are still undergoing human clinical trials, anticomplement therapy may represent a novel therapeutic strategy for preventing myocardial I–R injury in humans.

**Summary**

Vascular I–R injury has been shown to contribute to a variety of adverse outcomes. In its severest form, I–R injury may clinically result in MODS or death. The pathogenesis of I–R is complex and involves both a local
and systemic inflammatory response characterized by oxidant production, complement activation, leucocyte–endothelial cell adhesion, transendothelial leucocyte migration, platelet–leucocyte aggregation, increased microvascular permeability and decreased endothelium-dependent relaxation. At the same time, several protective pathways which may be critical in limiting excessive tissue inflammation and barrier breakdown have recently been described. Although our understanding of the basic pathophysiology of I–R injury has significantly advanced in the last decade, these experimentally derived ideas have yet to be fully integrated into clinical practice. Further, the treatment of I–R injury is confounded by the fact that inhibition of I–R-associated inflammation might disrupt protective physiological responses or result in immunosuppression. Thus, timely reperfusion of the ischaemic area at risk remains the cornerstone of clinical practice. Nevertheless, therapeutic approaches like ischaemic preconditioning, controlled reperfusion and antioxidant, complement or neutrophil therapy may contribute to preventing or limiting I–R injury. Additionally, novel therapeutic targeting of specific anti-inflammatory and barrier-protective pathways (e.g. specific adenosine receptor activation) may hold future promise.

Conflict of interest statement:

Dr Collard has served as a Principal Investigator in the clinical trials of Alexion Pharmaceuticals and Avant Immunotherapeutics. Dr. Eltzschig has no conflicts.

References


21 Thompson LF, Eltzschig HK, Ibla JC et al. Critical role for ecto-5′-nucleotidase (CD73) in vascular permeability during hypoxia. Submitted for publication.


